

buosumab solution for injection (Crysvita®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2588	for the treatment of X-linked hypophosphataemia in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease.	Available in line with local or regional guidance	17/01/2024	17/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8025/buosumab-crysvita-reassessment-final-dec-2023-for-website.pdf				

pembrolizumab concentrate for solution for infusion (Keytruda®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2589	<p>As monotherapy for adults with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in the following settings:</p> <ul style="list-style-type: none"> • treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine-based combination therapy. <p>As monotherapy for the treatment of the following MSI-H or dMMR tumours in adults with:</p> <ul style="list-style-type: none"> • advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation; • unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. 	Available in line with local or regional guidance	17/01/2024	17/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8026/pembrolizumab-keytruda-final-dec-2023-for-website.pdf				

belantamab mafodotin powder for concentrate for solution for infusion (Blenrep®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2597	as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.	Not routinely available as not recommended for use in NHS Scotland	17/01/2024	17/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8029/belantamab-blenrep-final-dec-2023-for-website.pdf				

axicabtagene ciloleucel (Yescarta)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2646	Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.	Not routinely available as not recommended for use in NHS Scotland	17/01/2024	17/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8028/axicabtagene-ciloleucel-non-sub-final-dec-2023-for-website.pdf				

setmelanotide (Imcivree®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2647	Treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adults and children 6 years of age and above.	Not routinely available as not recommended for use in NHS Scotland	17/01/2024	17/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8027/setmelanotide-imcivree-non-sub-final-dec-2023-for-website.pdf				